Investigators from the Ontario Institute for Cancer Research and the University Health Network have synthesized triazolopyridopyrimidine and dihydroimidazopyridopyrimidine derivatives acting as eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer and peripheral neuropathy.
Deciphera Pharmaceuticals LLC has divulged eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.
In tumors with amino acid deprivation, eIF-2α kinase GCN2 is activated and triggers a signaling response to promote cell survival and proliferation. This is important in high metabolically active hematological cancers, such as acute myeloid leukemia (AML).
Dong-A ST Co. Ltd. has reported new eukaryotic translation initiation factor 2α kinase 4 (GCN2) inhibitors as potentially useful for the treatment of cancer, infections, neurodegenerative and metabolic diseases.
Researchers at Aston Science Co. Ltd. and Korea Research Institute of Chemical Technology have synthesized phenylsulfonamide derivatives acting as eukaryotic translation initiation factor 2-α kinase 1 (HRI) and/or translation initiation factor 2-α kinase 3 (PERK) and/or eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Touchstone Innovations Ltd. has disclosed eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, myocardial ischemia, diabetic cardiopathy, cardiotoxicity, nonalcoholic fatty liver disease and diabetic retinopathy.
Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.
Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.
At the recent Society for Immunotherapy of Cancer meeting, researchers from Dong-A ST Co. Ltd. presented preclinical data for the novel small-molecule general control nonderepressible 2 (GCN2) inhibitor, DA-4507, being developed for the treatment of cancer.
